These data show that Pr2x7 gene deletion protects mice from HFD-induced NASH, possibly through blunted activation of NLRP3 inflammasome, suggesting that PR2X7 and NLRP3 may represent novel therapeutic targets. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.